Buprenorphine/Naloxone Initiation Guidelines

Pre-Initiation Requirements

The American College of Emergency Physicians recommends initiating buprenorphine/naloxone only when the patient is in active opioid withdrawal, confirmed by Clinical Opiate Withdrawal Scale (COWS) score >8, and start with 4-8 mg sublingual based on withdrawal severity, targeting a total first-day dose of 16 mg for most patients 1, 2
For short-acting opioids, such as heroin or morphine IR, initiation should occur more than 12 hours since last use, while for extended-release formulations like OxyContin, it should be more than 24 hours since last use, and for methadone maintenance, more than 72 hours since last use 1, 2

The standard initial dose of buprenorphine/naloxone is 4-8 mg sublingual, based on withdrawal severity, with reassessment after 30-60 minutes for response, and a target total first-day dose of 16 mg for most patients 1, 2
The maintenance dose range is typically 16 mg daily, which can range from 4-24 mg daily, with dosing administered once daily or split into twice-daily dosing if needed 1

The American Heart Association and other guidelines warn against administering buprenorphine to intoxicated patients or those with contraindications such as QT-prolonging medications due to cardiac arrhythmia risk 1, 2, 3
Monitoring for respiratory depression, especially during initiation and dose increases, and watching for signs of serotonin syndrome if combined with serotonergic agents, is crucial 3, 4

Strongly consider offering overdose prevention education, take-home naloxone kit, hepatitis C and HIV screening, and reproductive health counseling at discharge 1, 2

Buprenorphine/naloxone combined with counseling and behavioral therapies provides a "whole-patient" approach that has demonstrated effectiveness and saves lives, showing better short-term improvement in treatment retention and reduced illicit opioid use compared to referral or brief intervention alone 1, 2

The Centers for Disease Control and Prevention recommends urine drug testing before starting opioid therapy to identify concurrent substance use, which can increase overdose risk, in the context of chronic opioid pain management, but this applies differently to medication-assisted treatment of opioid use disorder 5, 6
Drug testing before Suboxone initiation can be useful to confirm opioid use if the clinical history is unclear, according to guidelines that may inform medication-assisted treatment protocols 5
The American Medical Association suggests that drug testing should never delay treatment initiation when a patient presents in active withdrawal and meets clinical criteria, emphasizing the importance of timely access to care 5, 6
Guidelines from relevant medical societies indicate that dismissing patients based on drug test results showing polysubstance use represents a missed opportunity for lifesaving treatment, highlighting the need for a nuanced approach to substance use disorder treatment 5, 6

The CDC recommends baseline urine drug testing before initiating chronic opioid therapy for pain management to establish a substance‑use history and reduce misuse risk. Evidence level: guideline recommendation. 7
The Clinical Infectious Diseases guideline (2017) advises that baseline urine drug testing be applied universally to all patients receiving opioids for chronic pain to prevent bias and stigmatization. Evidence level: guideline recommendation. 8

The Annals of Internal Medicine (2017) states that federal guidelines explicitly indicate drug testing must not be used as a barrier to accessing buprenorphine for OUD; testing is a clinical safety tool, not a prerequisite for prescribing. Evidence level: guideline recommendation. 9

The Annals of Internal Medicine (2017) reports that the federal X‑waiver requirement for buprenorphine prescribing was eliminated in 2023, and insurers are urged to remove prior‑authorization limits that impede treatment. Evidence level: policy update. 9

JAMA (2016) warns that refusing to dispense buprenorphine because a patient lacks a toxicology screen violates the principle of patient non‑abandonment and constitutes an unjustified barrier to lifesaving therapy. Evidence level: expert commentary. 10
JAMA (2016) clarifies that checking Prescription Drug Monitoring Programs (PDMPs) is the prescriber’s responsibility; pharmacies should not require PDMP verification as a condition for dispensing buprenorphine. Evidence level: expert commentary. 10

Annals of Internal Medicine (2017) recommends that prescribers reference federal guidelines when contacting pharmacies to confirm that no toxicology screen is required for buprenorphine initiation, and to address any remaining pharmacy concerns (e.g., DEA waiver verification, which is no longer needed). Evidence level: guideline recommendation. 9